Application of liquid biopsy-based targeted capture sequencing analysis to improve the precision treatment of non-small cell lung cancer by tyrosine kinase inhibitors.
drug reactions
lung cancer
non-small cell lung cancer
Journal
BMJ open respiratory research
ISSN: 2052-4439
Titre abrégé: BMJ Open Respir Res
Pays: England
ID NLM: 101638061
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
received:
16
11
2021
accepted:
07
01
2022
entrez:
29
1
2022
pubmed:
30
1
2022
medline:
24
3
2022
Statut:
ppublish
Résumé
Targeted therapy of patients with non-small cell lung cancer (NSCLC) who harbour sensitising mutations by tyrosine kinase inhibitors (TKIs) has been found more effective than traditional chemotherapies. However, target genes status (eg, epidermal growth factor receptor ( Plasma samples from patients with NSCLC who showed resistance to the first/second-generation A total of 24 plasma cell-free DNA (cfDNA) samples were tested by the targeted capture sequencing assay. 33.3% (8/24) cfDNA samples were positive for The targeted capture sequencing test can support comprehensive molecular analysis needed for TKIs treatment, which is promising to be clinically applied for the improved precision treatment of NSCLC.
Sections du résumé
BACKGROUND
Targeted therapy of patients with non-small cell lung cancer (NSCLC) who harbour sensitising mutations by tyrosine kinase inhibitors (TKIs) has been found more effective than traditional chemotherapies. However, target genes status (eg, epidermal growth factor receptor (
METHODS
Plasma samples from patients with NSCLC who showed resistance to the first/second-generation
RESULTS
A total of 24 plasma cell-free DNA (cfDNA) samples were tested by the targeted capture sequencing assay. 33.3% (8/24) cfDNA samples were positive for
CONCLUSION
The targeted capture sequencing test can support comprehensive molecular analysis needed for TKIs treatment, which is promising to be clinically applied for the improved precision treatment of NSCLC.
Identifiants
pubmed: 35091437
pii: 9/1/e001154
doi: 10.1136/bmjresp-2021-001154
pmc: PMC8804681
pii:
doi:
Substances chimiques
Protein Kinase Inhibitors
0
ErbB Receptors
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: II has received honorarium for consultation from AstraZeneca, Roche, Bayer. The other authors of this study declare that they have no competing interests.
Références
Ann Oncol. 2018 Jan 1;29(suppl_1):i10-i19
pubmed: 29462254
Lung Cancer. 2019 Jan;127:96-102
pubmed: 30642559
Front Oncol. 2019 Mar 05;9:129
pubmed: 30891428
Mol Clin Oncol. 2019 Aug;11(2):127-131
pubmed: 31316771
Cells. 2018 Nov 15;7(11):
pubmed: 30445769
Nature. 2018 Jan 24;553(7689):446-454
pubmed: 29364287
Mol Cancer. 2018 Feb 19;17(1):53
pubmed: 29455669
Ann Oncol. 2014 Feb;25(2):423-8
pubmed: 24478319
Cancer Biol Ther. 2019;20(8):1057-1067
pubmed: 30990132
Mol Med. 2019 Apr 27;25(1):15
pubmed: 31029076
Oncol Lett. 2018 Nov;16(5):6431-6436
pubmed: 30405780
Curr Oncol. 2018 Apr;25(2):163-169
pubmed: 29719432
Oncotarget. 2017 Feb 14;8(7):12501-12516
pubmed: 27980215
J Thorac Oncol. 2018 Jun;13(6):e89-e91
pubmed: 29596911
Sci Rep. 2017 Apr 3;7(1):583
pubmed: 28373672
Oncotarget. 2016 Sep 6;7(36):58492-58499
pubmed: 27542267
Respir Med Case Rep. 2019 Jul 10;28:100901
pubmed: 31367517
Trends Pharmacol Sci. 2019 Mar;40(3):172-186
pubmed: 30736982
Eur Respir J. 2017 Mar 2;49(3):
pubmed: 28254765
Oncotarget. 2018 Apr 6;9(26):18529-18539
pubmed: 29719623
J Hematol Oncol. 2016 Jul 22;9(1):59
pubmed: 27448564
J Mol Diagn. 2017 Sep;19(5):722-732
pubmed: 28723342
Sci Rep. 2016 Oct 13;6:35249
pubmed: 27734950
J Hematol Oncol. 2019 Jun 21;12(1):63
pubmed: 31227004
Eur J Cancer. 2018 Jan;88:1-9
pubmed: 29175734
Clin Chim Acta. 2019 Aug;495:481-486
pubmed: 31125533
Transl Lung Cancer Res. 2019 Oct;8(5):584-592
pubmed: 31737495
Nat Med. 2014 May;20(5):548-54
pubmed: 24705333
Nat Rev Clin Oncol. 2018 Jun;15(6):348-349
pubmed: 29599475
J Thorac Oncol. 2017 Mar;12(3):567-572
pubmed: 27923714
Cancer Med. 2017 Jan;6(1):154-162
pubmed: 28000387
PLoS One. 2017 Sep 19;12(9):e0183715
pubmed: 28926605
Cancer Discov. 2012 Oct;2(10):922-33
pubmed: 22956644
Nat Biotechnol. 2016 May;34(5):547-555
pubmed: 27018799
Clin Cancer Res. 2016 Dec 1;22(23):5772-5782
pubmed: 27601595
Nat Methods. 2014 Feb;11(2):121-2
pubmed: 24481215